A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients with Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506976-28-00

Acronym

IPH6501-101

Enrollment

Registered

2024-03-25

Start date

2024-05-16

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma

Brief summary

MTD or highest tested dose evaluation, Safety and tolerability analysis

Detailed description

Efficacy analysis, Pharmacokinetics and Immunogenicity analysis

Interventions

DRUGIPH6501

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
MTD or highest tested dose evaluation, Safety and tolerability analysis	—

Secondary

Measure	Time frame
Efficacy analysis, Pharmacokinetics and Immunogenicity analysis	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026